Navigation Links
Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
Date:10/18/2011

EAST BRUNSWICK, N.J. and IRVINE, Calif., Oct. 18, 2011 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and Stason Pharmaceuticals Inc. today announced they had entered into a collaboration agreement regarding the development of generic oral oncology products. Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories. Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

"This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio," said Jonathan Embleton, Chief Business Officer for Amerigen. "We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration."

"We have been working hard to leverage our high containment development and manufacturing capabilities," said Jim Fang, Chief Operating Officer for Stason. "This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal." 

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All of Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About Stason

Stason Pharmaceuticals Inc. is a California-based pharmaceutical company involved in the development and manufacture of oral pharmaceuticals products. Stason develops products for itself as well as providing contract development and manufacturing services to the industry. Stason operates out of an FDA inspected 16,000 sq. ft. manufacturing facility capable of handling SafeBridge Catetgory I-IV, high containment and high potency compounds.  

Contact:
Michelle Valsera
+1-732-993-9827
mvalsera@amerigenpharma.com


'/>"/>
SOURCE Amerigen Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D ... answer as physics and manufacturing combine to progress molecular radiotherapy ... existing SPECT systems are unable to accurately quantify the radiation ... limited information regarding the success of this radiotherapy treatment has ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... management assistance and financial planning services to families and business owners in northern ... event that promises to provide support to area adults with developmental challenges. , ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... ... 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush University ... of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine Leadership ... This prestigious award is given annually to honor those who have made a significant ...
(Date:7/21/2017)... ... July 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... of violence and aggression to solve problems and pleads with world leaders to be more ... forces do not bring peace. He says there is a peaceful and positive way to ...
Breaking Medicine News(10 mins):